Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
ConditionEssential Hypertension
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19+
SponsorChong Kun Dang Pharmaceutical
About this trial
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Eligibility criteria
Qualifiers
Participants who are 19 years old or older.
Participants who have voluntarily decided to participate in this clinical trial and signed ICF.
Disqualifiers
Participants with a history of secondary hypertension or suspected secondary hypertension.
Participants with a orthostatic hypotension.
Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.
Participants with type 1 diabetes or poorly controlled diabetes.
Trial design
Treatments tested in this trial
- Sacubitril∙Valsartan(dose maintenance)
- Sacubitril∙Valsartan(dose increasing)
- Valsartan
Treatment groups
324 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov